TET2 and acute myeloid leukemia: A recent study reached the conclusion that the presence of ARCH was associated with a clearly increased risk of developing AML: particularly, mutations in IDH1, IDH2, TP53 (tumor protein 53), DNMT3A, TET2 and spliceosome genes increased the risk of developing AML; increased progression to AML was seen for those with >1 mutated gene by targeted sequencing (increased complexity) and ≥10% variant-allele fraction; interestingly, all patients with TP53 or IDH1/IDH2 mutations developed AML [11].